OncoPharm
John Bossaer
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Episodes
Mentioned books
Sep 9, 2022 • 16min
Biliary Tract Cancer & Pemigatinib (unrelated) Updates
Updates on billiary track cancer - a role for durvalumab?
And pemigatinib - an approval in r/r myeloid/lymphoid neoplasms.
Plus, an oral suspension of ibrutinib is approved and more evidence ICI combination should be given early in BRAF-mutated metastatic melanoma (rather than waiting until disease progression on TKIs)
Sep 1, 2022 • 17min
Temozolomide + RT For GBM
The Landmarks of OncoPharm series return to discuss the now standard-of-care temozolomide + RT for glioblastoma multiforme (GBM)
Stupp et al: https://www.nejm.org/doi/full/10.1056/NEJMoa043330
Effect of MGMT (the gene, not the band) on temozolomide effect (from the same NEJM issue) referenced, thought not discussed in this episode: https://www.nejm.org/doi/full/10.1056/NEJMoa043331
Aug 25, 2022 • 39min
All About Asparaginase
Dr. Amir Ali joins the Pod to cover the Foundations of OncoPharm on asparaginase products
Aug 18, 2022 • 15min
HER2 Mutated NSCLC
In light of trastuzumab deruxtecan's approval for HER-mutated NSCLC, it's worthwhile to look back at the history of HER-targeted therapy in NSCLC and why/how targeted HER-mutated disease will affect practice.
Aug 11, 2022 • 15min
Updated Adjuvant Atezolizumab Data (& more)
New OS data is out for adjuvant atezolizumab in NSCLC - how does it compare to the original DFS data?
Plus, lots of recent FDA expanded approvals to discuss.
Aug 4, 2022 • 14min
The Infamous Erlotinib Study
An infamous study that led to a drug approval of limited benefit, but still made its way into an episode of Better Call Saul.
Erlotinib + gemcitabine vs. gemcitabine: https://doi.org/10.1200/jco.2006.07.9525
Jul 28, 2022 • 21min
Long Term Follow-Up
Several recent large trials just released long term follow-up results on overall survival. We look at what how treatment principles may change based on these mature data.
ECHELON-1 - Hodgkin's (A+AVD vs. ABVD)
POLO - Pancreatic (olaparib maintenance vs. placebo)
Keynote 355 - mTNBC (pembrolizumab + chemo vs. chemo)
APHinity - adjuvant HER+ breast (pertuzumab/trastuzumab vs. trastuzumab)
E1912 - CLL (ibrutinib/rituximab vs. FCR)
Jul 14, 2022 • 21min
Living With Lupus
Discussion with a Lupus Nephritis patient (and Pharm.D. student) about manifestations and treatments of SLE and Lupus Nephritis.
Jul 7, 2022 • 17min
ICIs & PPIs - Something to Worry About?
Sifting through and summarizing lots of data on concomitant use of ICIs and PPIs.
Suggested readings:
1. All the drugs: https://pubmed.ncbi.nlm.nih.gov/33154150/
2. Pooled atezolizumab study: https://pubmed.ncbi.nlm.nih.gov/35183773/
3. Clostridium butyricum may be a thing: https://pubmed.ncbi.nlm.nih.gov/35655708/
4. AKI risk: https://doi.org/10.21873/invivo.12570
5. Is this all noise?: https://pubmed.ncbi.nlm.nih.gov/35280736/
6. Abx & PPIs: https://doi.org/10.3389/fimmu.2021.716317
Jun 30, 2022 • 10min
APAP + ICI: An emerging concern?
Acetaminophen (or paracetamol) & immune checkpoint inhibitors are ubiquitous in oncology practices. So, when new translational research suggests APAP may decrease the effectiveness - well that seems like something worth talking about.
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients: https://doi.org/10.1016/j.annonc.2022.05.010
Hepatotoxicity risk factors with ICIs: https://doi.org/10.1097/cji.0000000000000347
